What do you do when you’re so rich you could live to be a hundred and still not spend a noticeable fraction of your fortune? Buy yourself some more time. Literally.
The Amazon founder Jeff Bezos, 57 was reported last week to be among the backers of a new “rejuvenation company”, Altos Labs, a Silicon Valley start-up that has set its sights on understanding why we age and how we might prevent it — and ultimately work out how we might live for ever.
Bezos is not the only billionaire looking towards his end days. The men behind Google and Facebook are also dabbling in the dark art of manipulating mortality. But are they altruistically investing for the good of humanity — or is this.
Hey it’s Han from WrySci HX talking about a really interesting concept — the world’s first biological gaming console that uses nanopore technology to detect molecules, and turn these readouts into games! It’s called the Demonpore 64! More below ↓↓↓
Subscribe! =]
Please consider supporting 🙏
Patreon: https://www.patreon.com/wrysci_hx.
Follow me on twitter: https://twitter.com/han_xavier_
Or better yet, consider supporting any of the following!
Researchers at Université de Montréal and McGill University have discovered a new multi-enzyme complex that reprograms metabolism and overcomes “cellular senescence,” when aging cells stop dividing.
In their study published today in Molecular Cell, the researchers show that an enzyme complex named HTC (hydride transfer complex) can inhibit cells from aging.
“HTC protects cells from hypoxia, a lack of oxygen that normally leads to their death,” said senior author Gerardo Ferbeyre, an UdeM biochemistry professor and principal scientist at the CRCHUM, the university’s affiliated teaching hospital research center.
Reducing naturally occurring errors in protein synthesis (production) improves both health and lifespan, finds a new study in simple model organisms led by researchers at UCL and MRC London Institute of Medical Sciences.
The novel findings, published in Cell Metabolism, are the first to demonstrate a direct link between fewer protein mistakes and longevity.
Explaining the study, lead author Dr. Ivana Bjedov (UCL Cancer Institute), said: We commonly hear about DNA mutations, which can cause cancer, and are considered one of the underlying causes of ageing.
Citicoline, a drug that is naturally found in the body, is commonly used to treat a number of brain injuries and illnesses. For quite some time, doctors have prescribed it for strokes, vascular dementia, Parkinson’s disease, and general aging of the brain. Patients usually see improvement when taking the drug because the body uses it to create and repair cell membranes and lower the presence of free radicals, as noted in the Clinical Interventions in Aging Journal. (Free radicals, which are unstable molecules, can damage cells in the body and are associated with aging and illness.)
Now, researchers from the NYU Grossman School of Medicine have found evidence that citicoline can also be used to treat glaucoma. Normally, glaucoma is treated by removing fluid buildup in the eye, which creates pressure and wears down the cells in the eye and the nerves connecting to the brain. Though monitoring fluid buildup is important, glaucoma can still worsen after the pressure on the eye has been relieved.
Because the herpesvirus sits in neurons forever, there is speculation it is connected to neurodegenerative diseases. The immune system requires inflammation to constantly fight off the virus, and neurons have some degree of damage because of this continuous immune response, according to Dr. Tibor Valyi-Nagy, professor of pathology, director of neuropathology at UIC and research collaborator on the study.
Summary: Researchers discovered mutations of the OPTN gene resulted in increased herpesvirus 1 growth in the brains of mice, leading to the death of local neurons. This resulted in accelerated neurodegeneration. OPTN deficiency was also associated with impairments in immune response. While these findings are specific to the HSV-1 virus, researchers believe the findings may apply to up to eight herpesvirus infections.
Source: University of Illinois at Chicago
A new study by researchers at University of Illinois Chicago suggests that when the protein optineurin, or OPTN, is present in cells it restricts the spread of HSV-1, the herpes simplex virus type 1.
In a “first of its kind” study, researchers also found a potential direct connection between neurodegenerative diseases, such as Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), glaucoma, and the herpesvirus, said Dr. Deepak Shukla, the Marion H. Schenk Esq. Professor in Ophthalmology for Research of the Aging Eye, and vice chair for research at UIC.
The book The Illusion of Knowledge, by Harold Katcher, was launched on September 4th 2021 at Book Passage Ferry Building, San Francisco/CA. The book was published by NTZ, a publisher specialized on the rejuvenation field.
Longer, Healthier, And More Productive Lives — Dr. Jean Accius Ph.D., Senior Vice President, AARP
Dr. Jean C. Accius, PhD, is Senior Vice President, AARP Global Thought Leadership (https://www.aarp.org/). Dr. Accius leads a team in positioning AARP (formerly known as the American Association of Retired Persons) as a global thought leader, identifying emerging trends around the world, cultivating and elevating new ideas, forging global strategic alliances that become the foundation for collaboration and sparking bold solutions to change systems and improve the lives of the global population as it ages.
Dr. Accius is a passionate champion and catalyst for changing how the world sees and values aging. He is an internationally recognized thought leader on aging, longevity, equity, health systems transformation and modernizing the delivery and financing of long-term care. With tri-sector experience and deep knowledge, he has a strong track record of building high-performing teams, managing cross-functional operations and processes, and developing innovative and actionable solutions, policies, and programs to close the opportunity gap so that everyone can live longer, healthier and more productive lives.
A highly sought after author and speaker, Dr. Accius has been quoted by or appeared in numerous media outlets, including The New York Times, Forbes, TIME Magazine, USA Today, Reuters, Politico, Next Avenue, ESPN’s Undefeated, Rolling Out, NationSwell, Congressional Quarterly, and Huffington Post. In 2,020 he facilitated several sessions at the 50th annual World Economic Forum in Davos, Switzerland and also engaged nearly 300 leaders across industries and sectors, including 20 ambassadors and many delegates, at the United Nations.
Dr. Accius is a member of the National Association of Corporate Directors and has held a variety of board and advisory positions including Justice in Aging, the American Society on Aging, Leadership Maryland and the American University School of Public Affairs Board of Advisors.
Dr. Accius is an Executive Leadership Council Fellow, member of G100’s Transformational Leadership Network, and holds a bachelor’s degree in hospitality administration and a master’s degree in aging studies from the Claude Pepper Institute at Florida State University. He also holds a Ph.D. in public administration from American University. Dr. Accius is a graduate of Leadership Maryland’s Class of 2,014 the Harvard T.H. Chan School of Public Health program on health reform, and Stanford University’s Graduate School of Business Corporate Innovation program.
While is seems like the majority of the longevity space is currently overly captivated by the Aubrey de Grey/SENS debacle, the U.S. National Academy of Sciences, Healthy Longevity Global Innovator Summit is now beginning — Most interestingly, former R&D Head at PepsiCo, Dr. Mehmoud Khan, will be speaking in his new role as CEO of the Hevolution Foundation; a potential multi-billion $$$ initiative with a longevity angle — Everyone should keep their eye on this one…
The National Academy of Medicine (NAM) will hold its inaugural Healthy Longevity Global Innovator Summit in September 2,021 with support from Johnson and Johnson Innovation and The John A. Hartford Foundation. The event will be virtual and held over three days, September 13 14, and 22 and feature an immersive, interactive digital venue with unique opportunities to engage and connect.
The Innovator Summit will honor the 154 international Healthy Longevity Catalyst Awardees from 2020 and bring together industry leaders, academics, researchers, scientists, and entrepreneurs whose work contributes to the field of healthy longevity. Attendees will learn about the early-stage, award-winning innovations, hear from leaders in the field of healthy longevity, and take advantage of various opportunities to interact directly with other attendees, with a view to fostering interdisciplinary and cross-sector collaboration.
The event will feature remarks from the President of the National Academy of Medicine, Dr. Victor Dzau, and Catalyst Award Sponsors, Dr.William Hait, Global Head of Johnson & Johnson External Innovation, and Dr. Terry Fulmer, President of the John A. Hartford Foundation. Visionary keynote speakers will share insights into launching biotechnology start-ups and opportunities for groundbreaking science in the field of longevity. Participants will also be able to enjoy a robust selection of breakout sessions and the chance to network with Catalyst Award winners, researchers, venture capitalists, and more in one-on-one and small group settings.
